Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-β1 and plasminogen activator inhibitor 1

Chinese Medical Journal

Volumn 124, Issue 13, 2011, Pages 1923-1927

  Li, Xin Xia ^a,b   Li, Ning ^a,c   Ban, Cheng Jun ^a   Zhu, Min ^a   Xiao, Bai ^a   Dai, Hua Ping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Gene polymorphism; Genetic susceptibility; Idiopathic pulmonary fibrosis; Plasminogen activator inhibitor 1; Transforming growth factor beta 1

Indexed keywords

CYTIDINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; FIBROSING ALVEOLITIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79960058465     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.13.001     Document Type: Article

References (29)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
2. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolit is in the United Kingdom. Thorax 2000; 55: 143-146.
3. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-342.
4. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816.
5. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165: 1322-1328.
6. Markart P, Ruppert C, Wygrecka M, Schmidt R, Korfei M, Harbach H, et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J 2007; 29: 134-137.
7. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J 2005; 25: 915-927.
8. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004; 113: 148-157.
9. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
10. Roberts CJ, Birkenmeier TM, McQuillan JJ, Akiyama SK, Yamada SS, Chen WT, et al. Transforming growth factor beta stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts. J Biol Chem 1988; 263: 4586-4592.
11. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extra cellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991; 88: 6642-6646.
12. Yong, SJ, Adlakha A, Limper, AH. Circulating transforming growth factor-beta (1): a potential marker of disease activity during idiopathic pulmonary fibrosis. Chest 2001; 120 (1 Suppl): 68S-70S.
13. Santana A, Saxena B, Noble NA, Gold LI, Marshall BC. Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1995; 13: 34-44.
14. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768-776.
15. Denis M. Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis. Immunology 1994; 82: 584-590.
16. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-1020.
17. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8: 93-97.
18. Suthanthiran M, Li BG, Song JO, Ding RC, Sharma VK, Schwartz JE, et al. Transforming growth factor-β1 hyper expression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sic 2000; 97: 3479-3484.
19. El-Gamel A, Awad M, Sim E, Hasleton P, Yonan N, Egan J, et al. Transforming growth factor-beta1 and lung allograft fibrosis. Eur J Cardiothorac Surg 1998; 13: 424-430.
20. Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK, et al. TGF-beta (1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000; 55: 459-462.
21. Mori M, Kida H, Morishita H, Goya S, Matsuoka H, Arai T, et al. Micro satellite instability in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2001; 24: 398-404.
22. Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, et al. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 431-435.
23. Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986; 133: 437-443.
24. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
25. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or over express the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237.
26. Johanna GB, Michiel LB, Frits H, Cornelis K, Diederick EG. The 4G5G plymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 2003; 101: 1841-1844.
27. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, et al. Metabolic determinats are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 1998; 18: 84-91.
28. Kim KK, Flaherty KR, Long Q, Hattori N, Sisson TH, Colby TV, et al. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med 2003; 9: 52-56.
29. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155: 242-248.